E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Cystic Fibrosis with chronic rhinosinusitis |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Variations in the Sino-nasal-outcome test SNOT-20 adapt CF primary nasal parameters: obstruction of nasal breathing, sneeze stimulus, permanent nose running, thick-mucous nasal discharge, earaches
|
|
E.2.2 | Secondary objectives of the trial |
1. Changes of the Sino-nasal-outcome test SNOT-20 adapt CF (secondary nasal parameter and general quality of life and total SNOT 20 adapt CF- score) 2. Changes of pathological alterations visible in MRT images of nose and paranasal sinuses (in selected patients) 3. Changes in the nasal lavage fluid (cytology, cytokines, DNA fragments, microbiology) and in the serological markers of inflammation (CrP, IgG, blood count) 4. Changes in rhinoscopic findings 5. Changes in rhinomanometric findings 6. Incidence of rhinosinusitic and pulmonary exacerbations during therapy 7. Need for decongestants or nasal lavage during treatment
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subject has a confirmed diagnosis of cystic fibrosis based on: 3 positive sweat chloride tests and/or genetic characterisation. 2. Subject is 5 years of age or older. 3. Subject has chronic or recurrent rhinosinusitic disorders. 4. Subject is able to comply with the Inhalation procedures scheduled in the protocol. 5. Subject is able to comply with the nasal lavage procedures scheduled in the protocol. 6. Therapy is completely possible without any restrictions. 5. Women of childbearing potential are only included into the study, if they are using an effective method of birth control during the protocol (e.g. implants, combined oral contraceptives, injectables, some IUDs, sexual abstinence or vasectomised partner). |
|
E.4 | Principal exclusion criteria |
1. Subject has a critical condition defined as: FEV1 < 30% and / or SaO2 < 93% without O2-substitution; need of O2-substitution 2. Subject had an ENT surgery within 6 months prior to study 3. Subject shows signs of nasal bleeding 4. Subject has an ear drum perforation 5. Subject had an acute rhinosinusitis or a pulmonary exacerbation at study entry with need of additional systemic antibiotic therapy 6. Subject has a new therapy with nasal topic steroids during treatment interval 7. Subject has a new systemic steroid therapy 8. Subject is unlikely to comply with the procedures scheduled in the protocol 9. Subject has a known allergic reaction to the medication 10. Subject is pregnant or breastfeeding 11.Patient participates in another clinical trial within 30 days prior to study entry or 30 days after end of the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Comparison of nasal inhalation therapy: 4 weeks of pulmozyme versus 4 weeks NaCl 0,9% including a 4 weeks wash out period in between both periods. The trial will be performed as randomized double blind placebo controlled study including a cross over of verum (Pulmozyme) and placebo (NaCl 0,9%)
Primary end points will be changes in quality of life score (SNOT-20 ad CF). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will be reached, when the patient completes as well the verum, placebo and wash out period or at any time when he requires the interruption of the participation. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |